Pharma Focus Asia

Novel Ivonescimab (PD-1/VEGF Bispecific Antibody Developed for Non-Small-Cell Lung Carcinoma (NSCLC) patients

Akeso Biopharma developed novel Ivonescimab (PD-1/VEGF bispecific antibody in combination with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) patients.

Novel Ivonescimab is applicable for patients who have failed to respond to prior PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.

Ivonescimab is the first-in-class PD-1/VEGF bi-specific antibody blocking PD-1 binding toPD-L1 and PD-L2 and it also blocks VEGF binding to VEGF receptors. When PD-1 antibody combined with VEGF blocking agents have shown efficient results in different tumors such as renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma.

Ivonescimab, as a single agent can block these two VEGF and PD-1 antibodies and enhance the antitumor activity, compared to combination therapy.

To treat EGFR-mutatedlocally advanced or metastatic NSCLC patients, AK112 is combined with chemotherapy, failed to respond to EGFR-TKI treatment, having completed Phase III clinical trials patient enrollment.

PD-1/L1 monoclonal antibody in combination with platinum-based chemotherapy is the first-line therapy for patients with advanced NSCLC.

AK112 is the only drug candidate approved for NSCLC patients with PD-(L)1 resistant lung cancer treatment in China.

China National Medical Products Administration (NMPA) grants Breakthrough Therapy Designation (BTD) for Ivonescimab (PD-1/VEGFbispecific antibody for Non-Small-Cell Lung Carcinoma (NSCLC).

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024